Posted by Michael Wonder on 17 Jul 2023
Karyopharm receives FDA fast track designation for selinexor for the treatment of myelofibrosis
17 July 2023 - Regulatory designation includes primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis.
Karyopharm Therapeutics today announced that the US FDA has granted fast track designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.
